FDA 483 OBSERVATION · #1302 OF 1,932 MOST-CITED

Causing contamination, increasing risks

FDA cited this observation 11 times across 11 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation11
BY FISCAL YEAR
FY20252
FY20241
FY20221
FY20211
FY20192
FY20181
FY20172
FY20161

How FDA worded it — real examples

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.

Nelson Laboratories, LLC · Salt Lake City, Utah · Human Tissue for Transplantation · 2025-07-30

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing.

Berkeley Advanced Biomaterials, LLC · Berkeley, California · Human Tissue for Transplantation · 2024-11-22

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing.

HealthTech Wound Care, Inc. · Salt Lake City, Utah · Human Tissue for Transplantation · 2023-12-08

HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing.

Osteolife Biomedical I LLC · Miami, Florida · Human Tissue for Transplantation · 2022-02-04

HCT/Ps were not processed in a way that does not increase the risk of introduction, transmission, or spread of communicable disease.

Bloodworks · Seattle, Washington · Human Tissue for Transplantation · 2021-07-16

HCT/Ps were not processed in a way that does not increase the risk of introduction, transmission, or spread of communicable disease.

Stratus BioSystems, LLC · Grapevine, Texas · Human Tissue for Transplantation · 2019-02-28

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Contamination control →Quality risk management →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →